Abbott (ABT) Q2 FY26 earnings call

Abbott delivered strong Q2 FY26 results, marked by accelerating sales growth and an upward revision to full-year EPS guidance, driven by momentum in key segments like Nutrition, Electrophysiology, Core Lab, and Cancer Diagnostics. The company is advancing a robust pipeline with several new product launches anticipated over the next 12 months, positioning it for sustained growth despite some short-term segment-specific challenges.